Aurinia Pharmaceuticals (AUPH) Stock Forecast & Price Target

Aurinia Pharmaceuticals is supported by LUPKYNIS, whose Q3/26 net product sales of $79.4MM rose 12% y/y and helped lift total revenue to $83.7MM, while Q3 net income of about $31.7MM came in ahead of estimates. The business also shows strong financial flexibility, ending Q3/26 with roughly $486.9MM in cash and investments and generating about $46.4MM of cash from operations, which supports continued commercial and R&D investment. The outlook is further strengthened by raised 2026 guidance, a favorable Teva settlement that may support exclusivity into December 2036, and aritinercept’s expansion into four indications, all of which improve long-term growth visibility.

Aurinia Pharmaceuticals is viewed negatively because its investment case is overwhelmingly dependent on LUPKYNIS, while aritinercept remains only an early-stage candidate with no value assigned in the downside case. The company faces meaningful patent overhang, with seven other generic filers in litigation and a modeled mid-2028 generic entry scenario that implies DCF-derived value of about $5.85 per share, or roughly $5.50 per share if exclusivity is lost in 2027. Beyond exclusivity risk, adoption could underperform expectations and new lupus nephritis competitors from better-capitalized pharma and biotech companies may pressure future sales and limit the durability of LUPKYNIS revenue.